Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges

Prescription patterns of ambrisentan in some cities of Colombia

“…[13][14][15]17,[20][21][22][23][24][25][26][27][28][29][30][31] Arterial hypertension was the most prevalent comorbidity in this report, which is consistent with the literature. 17,20,[26][27][28][29][30][31] Pulmonary arterial hypertension (Group 1) was the most prevalent, in line with other studies with real-world evidence, 20,22,23,25 and most of the patients had WHO Functional Class I; this differs from other reports in which the patients presented a more deteriorated functional class, 15,20,22,23,25,29 but the proportion of cases with home oxygen use was similar (33.3% vs. 21.6-30.2%). 24,28 The dosages of ambrisentan used were in accordance with the recommendations of the clinical practice Abbreviations: F, female; IQR, interquartile range; M, male; SD, standard deviation.…”

“… 13 , 14 , 15 , 17 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 Arterial hypertension was the most prevalent comorbidity in this report, which is consistent with the literature. 17 , 20 , 26 , 27 , 28 , 29 , 30 , 31 Pulmonary arterial hypertension (Group 1) was the most prevalent, in line with other studies with real‐world evidence, 20 , 22 , 23 , 25 and most of the patients had WHO Functional Class I; this differs from other reports in which the patients presented a more deteriorated functional class, 15 , 20 , 22 , 23 , 25 , 29 but the proportion of cases with home oxygen use was similar (33.3% vs. 21.6–30.2%). 24 , 28 …”

“…19 The WHO estimates that more than half of all medicines are improperly prescribed, dispensed, or sold and that half of all patients do not take them correctly. 19 The median age of the patients in this study was similar to that found in some studies in Asia (47.0-50.8 years) 20,21 and Europe (49.6-52.0 years), [22][23][24] but in other reports from Europe (61.0-61.6 years), 13,14,25 North America (62.7-68.1 years) 17,[26][27][28] and Oceania (60.0 years), 29 patients were older, 13,14,17,[25][26][27][28][29] and there was a predominance of women (82.1% vs. 61.0-79.0%). [13][14][15]17,[20][21][22][23][24][25][26][27][28][29][30][31] Arterial hypertension was the most prevalent comorbidity in this report, which is consistent with the literature.…”

“…19 The median age of the patients in this study was similar to that found in some studies in Asia (47.0-50.8 years) 20,21 and Europe (49.6-52.0 years), [22][23][24] but in other reports from Europe (61.0-61.6 years), 13,14,25 North America (62.7-68.1 years) 17,[26][27][28] and Oceania (60.0 years), 29 patients were older, 13,14,17,[25][26][27][28][29] and there was a predominance of women (82.1% vs. 61.0-79.0%). [13][14][15]17,[20][21][22][23][24][25][26][27][28][29][30][31] Arterial hypertension was the most prevalent comorbidity in this report, which is consistent with the literature. 17,20,[26][27][28][29][30][31] Pulmonary arterial hypertension (Group 1) was the most prevalent, in line with other studies with real-world evidence,…”

“… 3 , 4 , 6 , 7 In other studies on the pharmacological management of pulmonary hypertension, it has been shown that monotherapy predominates in most cases (51.0–95.1%). 17 , 22 , 26 , 27 , 28 , 29 This can be explained by the methodological differences of the studies, since some of them include only incident cases and others include both incidence and prevalence; it will also depend on the severity of the pathology, the level of risk, the tolerability of the drugs, the moment in which the research was carried out, and the recommendations in force at the time of the study. 3 , 4 , 6 , 7 , 17 , 22 , 26 , 27 , 28 , 29 …”